Two-year follow-up of macaques developing intermittent control of the human immunodeficiency virus homolog simian immunodeficiency virus SIVmac251 in the chronic phase of infection

Journal of Virology

Volumn 89, Issue 15, 2015, Pages 7521-7535

  Shytaj, Iart Luca ^a   Nickel, Gabrielle ^b   Arts, Eric ^b   Farrell, Nicholas ^c   Biffoni, Mauro ^a   Pal, Ranajit ^d   Chung, Hye Kyung ^d   LaBranche, Celia ^e   Montefiori, David ^e   Vargas Inchaustegui, Diego ^f   Robert Guroff, Marjorie ^f   Lewis, Mark G ^g   Sacha, Jonah B ^h   Palamara, Anna Teresa ^i,j   Savarino, Andrea ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^d ABL Associates Inc   (United States)

^e DUKE UNIVERSITY   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

^g BIOQUAL INC   (United States)

^h OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

ⁱ SAPIENZA UNIVERSITY OF ROME   (Italy)

^j IRCCS SAN RAFFAELE PISANA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AURANOFIN; BUTHIONINE SULFOXIMINE; GAG PROTEIN; GAMMA INTERFERON; GLUTATHIONE; NEUTRALIZING ANTIBODY; VIRUS RNA; ANTIVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIVIRAL ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOREACTIVITY; INFECTION CONTROL; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE ACTIVATION; VIRUS LOAD; VIRUS STRAIN; ANIMAL; DISEASE MODEL; DRUG EFFECTS; GENETICS; HIV INFECTIONS; HUMAN; IMMUNOLOGY; PHYSIOLOGY; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS; MACACA; MACACA MULATTA; SIMIAN IMMUNODEFICIENCY VIRUS;

ANIMALS; ANTIVIRAL AGENTS; CD4-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; FOLLOW-UP STUDIES; GENE PRODUCTS, GAG; HIV INFECTIONS; HUMANS; MACACA MULATTA; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VIRAL LOAD;

EID: 84937682389     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00396-15     Document Type: Article

References (51)

1. Trono D, Van Lint C, Rouzioux C, Verdin E, Barré-Sinoussi F, Chun TW, Chomont N. 2010. HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science 329:174-180. http://dx.doi.org/10.1126/science.1191047.
2. Van Rompay KK, Trott KA, Jayashankar K, Geng Y, LaBranche CC, Johnson JA, Landucci G, Lipscomb J, Tarara RP, Canfield DR, Heneine W, Forthal DN, Montefiori D, Abel K. 2012. Prolonged tenofovir treatment of macaques infected with K65R reverse transcriptase mutants of SIV results in the development of antiviral immune responses that control virus replication after drug withdrawal. Retrovirology 9:57. http://dx.doi.org/10.1186/1742-4690-9-57.
3. Mavigner M, Watkins B, Lawson B, Lee ST, Chahroudi A, Kean L, Silvestri G. 2014. Persistence of virus reservoirs in ART-treated SHIVinfected rhesus macaques after autologous hematopoietic stem cell transplant. PLoS Pathog 10:e1004406. http://dx.doi.org/10.1371/journal.ppat.1004406.
4. Lewis MG, DaFonseca S, Chomont N, Palamara AT, Tardugno M, Mai A, Collins M, Wagner WL, Yalley-Ogunro J, Greenhouse J, Chirullo B, Norelli S, Garaci E, Savarino A. 2011. Gold drug auranofin restricts the viral reservoir in the monkey AIDS model and induces containment of viral load following ART suspension. AIDS 25:1347-1356. http://dx.doi.org/10.1097/QAD.0b013e328347bd77.
5. Shah SK, Persaud D, Wendler DS, Taylor HA, Gay H, Kruger M, Grady C. 2014. Research on very early ART in neonates at risk of HIV infection. Lancet Infect Dis 14:797. http://dx.doi.org/10.1016/S1473-3099(14)70893-X.
6. Henrich TJ, Hanhauser E, Marty FM, Sirignano MN, Keating S, Lee TH, Robles YP, Davis BT, Li JZ, Heisey A, Hill AL, Busch MP, Armand P, Soiffer RJ, Altfeld M, Kuritzkes DR. 2014. Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases. Ann Intern Med 161:319-327. http://dx.doi.org/10.7326/M14-1027.
7. Sáez-Cirión A, Bacchus C, Hocqueloux L, Avettand-Fenoel V, Girault I, Lecuroux C, Potard V, Versmisse P, Melard A, Prazuck T, Descours B, Guergnon J, Viard JP, Boufassa F, Lambotte O, Goujard C, Meyer L, Costagliola D, Venet A, Pancino G, Autran B, Rouzioux C, ANRS VISCONTI Study Group. 2013. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy. ANRS VISCONTI Study. PLoS Pathog 9:e1003211. http://dx.doi.org/10.1371/journal.ppat.1003211.
8. Chirullo B, Sgarbanti R, Limongi D, Shytaj IL, Alvarez D, Das B, Boe A, DaFonseca S, Chomont N, Liotta L, Petricoin EI, Norelli S, Pelosi E, Garaci E, Savarino A, Palamara AT. 2013. A candidate anti-HIV reservoir compound, auranofin, exerts a selective 'anti-memory' effect by exploiting the baseline oxidative status of lymphocytes. Cell Death Dis 4:e944. http://dx.doi.org/10.1038/cddis.2013.473.
9. Roder C, Thomson MJ. 2015. Auranofin: repurposing an old drug for a golden new age. Drugs R D 15:13-20. http://dx.doi.org/10.1007/s40268-015-0083-y.
10. Shytaj IL, Norelli S, Chirullo B, Della Corte A, Collins M, Yalley-Ogunro J, Greenhouse J, Iraci N, Acosta EP, Barreca ML, Lewis MG, Savarino A. 2012. A highly intensified ART regimen induces long-term viral suppression and restriction of the viral reservoir in a simian AIDS model. PLoS Pathog 8:e1002774. http://dx.doi.org/10.1371/journal.ppat.1002774.
11. Shytaj IL, Chirullo B, Wagner W, Ferrari MG, Sgarbanti R, Corte AD, LaBranche C, Lopalco L, Palamara AT, Montefiori D, Lewis MG, Garaci E, Savarino A. 2013. Investigational treatment suspension and enhanced cell-mediated immunity at rebound followed by drug-free remission of simian AIDS. Retrovirology 10:71. http://dx.doi.org/10.1186/1742-4690-10-71.
12. Murakoshi H, Akahoshi T, Koyanagi M, Chikata T, Naruto T, Maruyama R, Tamura Y, Ishizuka N, Gatanaga H, Oka S, Takiguchi M. 4 March 2015. Clinical control of HIV-1 by cytotoxic T cells specific for multiple conserved epitopes. J Virol http://dx.doi.org/10.1128/JVI.00020-15.
13. Deng K, Pertea M, Rongvaux A, Wang L, Durand CM, Ghiaur G, Lai J, McHugh HL, Hao H, Zhang H, Margolick JB, Gurer C, Murphy AJ, Valenzuela DM, Yancopoulos GD, Deeks SG, Strowig T, Kumar P, Siliciano JD, Salzberg SL, Flavell RA, Shan L, Siliciano RF. 2015. Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. Nature 517:381-385. http://dx.doi.org/10.1038/nature14053.
14. Vint IA, Chain BM, Foreman JC. 1993. The interaction of auranofin and buthionine sulfoximine blocks activation of human peripheral T lymphocytes. Cell Immunol 152:152-161. http://dx.doi.org/10.1006/cimm.1993.1275.
15. Vargas-Inchaustegui DA, Xiao P, Tuero I, Patterson LJ, Robert-Guroff M. 2012. NK and CD4+ T cell cooperative immune responses correlate with control of disease in a macaque simian immunodeficiency virus infection model. J Immunol 189:1878-1885. http://dx.doi.org/10.4049/jimmunol.1201026.
16. Vargas-Inchaustegui DA, Xiao P, Demberg T, Pal R, Robert-Guroff M. 7 May 2015. Therapeutic envelope vaccination in combination with antiretroviral therapy temporarily rescues SIV-specific CD4(+) T celldependent NK cell effector responses in chronically infected rhesus macaques. Immunology http://dx.doi.org/10.1111/imm.12447.
17. Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, Koutsoukos M, Voss G, Goepfert P, Gilbert P, Greene KM, Bilska M, Kothe DL, Salazar-Gonzalez JF, Wei X, Decker JM, Hahn BH, Montefiori DC. 2005. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 79:10108-10125. http://dx.doi.org/10.1128/JVI.79.16.10108-10125.2005.
18. Romano JW, Shurtliff RN, Dobratz E, Gibson A, Hickman K, Markham PD, Pal R. 2000. Quantitative evaluation of simian immunodeficiency virus infection using NASBA technology. J Virol Methods 86:61-70. http://dx.doi.org/10.1016/S0166-0934(99)00184-6.
19. Lee EM, Chung HK, Livesay J, Suschak J, Finke L, Hudacik L, Galmin L, Bowen B, Markham P, Cristillo A, Pal R. 2010. Molecular methods for evaluation of virological status of nonhuman primates challenged with simian immunodeficiency or simian-human immunodeficiency viruses. J Virol Methods 163:287-294. http://dx.doi.org/10.1016/j.jviromet.2009.10.012.
20. Dunham RM, Gordon SN, Vaccari M, Piatak M, Huang Y, Deeks SG, Lifson J, Franchini G, McCune JM. 2013. Preclinical evaluation of HIV eradication strategies in the simian immunodeficiency virus-infected rhesus macaque: a pilot study testing inhibition of indoleamine 2,3-dioxygenase. AIDS Res Hum Retroviruses 29:207-214. http://dx.doi.org/10.1089/AID.2012.0162.
21. Diop OM, Gueye A, Dias-Tavares M, Kornfeld C, Faye A, Ave P, Huerre M, Corbet S, Barre-Sinoussi F, Müller-Trutwin MC. 2000. High levels of viral replication during primary simian immunodeficiency virus SIVagm infection are rapidly and strongly controlled in African green monkeys. J Virol 74:7538-7547. http://dx.doi.org/10.1128/JVI.74.16.7538-7547.2000.
22. Cline AN, Bess JW, Piatak M, Jr., Lifson JD. 2005. Highly sensitive SIV plasma viral load assay: practical considerations, realistic performance expectations, and application to reverse engineering of vaccines for AIDS. J Med Primatol 34:303-312. http://dx.doi.org/10.1111/j.1600-0684.2005.00128.x.
23. Chung HK, Unangst T, Treece J, Weiss D, Markham P. 2008. Development of real-time PCR assays for quantitation of simian betaretrovirus serotype-1,-2,-3, and-5 viral DNA in Asian monkeys. J Virol Methods 152:91-97. http://dx.doi.org/10.1016/j.jviromet.2008.05.021.
24. Ratcliff AN, Shi W, Arts EJ. 2013. HIV-1 resistance to maraviroc conferred by a CD4 binding site mutation in the envelope glycoprotein gp120. J Virol 87:923-934. http://dx.doi.org/10.1128/JVI.01863-12.
25. Burwitz BJ, Giraldo-Vela JP, Reed J, Newman LP, Bean AT, Nimityongskul FA, Castrovinci PA, Maness NJ, Leon EJ, Rudersdorf R, Sacha JB. 2012. CD8+and CD4+cytotoxic T cell escape mutations precede breakthrough SIVmac239 viremia in an elite controller. Retrovirology 9:91. http://dx.doi.org/10.1186/1742-4690-9-91.
26. Dereeper A, Guignon V, Blanc G, Audic S, Buffet S, Chevenet F, Dufayard JF, Guindon S, Lefort V, Lescot M, Claverie JM, Gascuel O. 2008. Phylogeny. fr: robust phylogenetic analysis for the non-specialist. Nucleic Acids Res 36:W465-W469. http://dx.doi.org/10.1093/nar/gkn180.
27. Cockerham LR, Siliciano JD, Sinclair E, O'Doherty U, Palmer S, Yukl SA, Strain MC, Chomont N, Hecht FM, Siliciano RF, Richman DD, Deeks SG. 2014. CD4+ and CD8+ T cell activation are associated with HIV DNA in resting CD4+ T Cells. PLoS One 9:e110731. http://dx.doi.org/10.1371/journal.pone.0110731.
28. Boasso A, Shearer GM. 2008. Chronic innate immune activation as a cause of HIV-1 immunopathogenesis. Clin Immunol 126:235-242. http://dx.doi.org/10.1016/j.clim.2007.08.015.
29. Borthwick NJ, Bofill M, Gombert WM, Akbar AN, Medina E, Sagawa K, Lipman MC, Johnson MA, Janossy G. 1994. Lymphocyte activation in HIV-1 infection. II. Functional defects of CD28-T cells. AIDS 8:431-441.
30. Griffith OW, Meister A. 1979. Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine). J Biol Chem 254:7558-7560.
31. Stephenson KE, Li H, Walker BD, Michael NL, Barouch DH. 2012. Gag-specific cellular immunity determines in vitro viral inhibition and in vivo virologic control following simian immunodeficiency virus challenges of vaccinated rhesus monkeys. J Virol 86:9583-9589. http://dx.doi.org/10.1128/JVI.00996-12.
32. Edwards BH, Bansal A, Sabbaj S, Bakari J, Mulligan MJ, Goepfert PA. 2002. Magnitude of functional CD8+ T-cell responses to the gag protein of human immunodeficiency virus type 1 correlates inversely with viral load in plasma. J Virol 76:2298-2305. http://dx.doi.org/10.1128/jvi.76.5.2298-2305.2002.
33. Zuñiga R, Lucchetti A, Galvan P, Sanchez S, Sanchez C, Hernandez A, Sanchez H, Frahm N, Linde CH, Hewitt HS, Hildebrand W, Altfeld M, Allen TM, Walker BD, Korber BT, Leitner T, Sanchez J, Brander C. 2006. Relative dominance of Gag p24-specific cytotoxic T lymphocytes is associated with human immunodeficiency virus control. J Virol 80:3122-3125. http://dx.doi.org/10.1128/JVI.80.6.3122-3125.2006.
34. Kiepiela P, Ngumbela K, Thobakgale C, Ramduth D, Honeyborne I, Moodley E, Reddy S, de Pierres C, Mncube Z, Mkhwanazi N, Bishop K, van der Stok M, Nair K, Khan N, Crawford H, Payne R, Leslie A, Prado J, Prendergast A, Frater J, McCarthy N, Brander C, Learn GH, Nickle D, Rousseau C, Coovadia H, Mullins JI, Heckerman D, Walker BD, Goulder P. 2007. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 13:46-53. http://dx.doi.org/10.1038/nm1520.
35. Julg B, Williams KL, Reddy S, Bishop K, Qi Y, Carrington M, Goulder PJ, Ndung'u T, Walker BD. 2010. Enhanced anti-HIV functional activity associated with Gag-specific CD8 T-cell responses. J Virol 84:5540-5549. http://dx.doi.org/10.1128/JVI.02031-09.
36. Jin MJ, Hui H, Robertson DL, Müller MC, Barré-Sinoussi F, Hirsch VM, Allan JS, Shaw GM, Sharp PM, Hahn BH. 1994. Mosaic genome structure of simian immunodeficiency virus from west African green monkeys. EMBO J 13:2935-2947.
37. Scott-Algara D, Didier C, Arnold V, Cummings JS, Sáez-Cirión A, Boufassa F, Rouzioux C, Hocqueloux L, Lambotte O. 2015. Posttreatment controllers have particular NK cells with high anti-HIV capacity: VISCONTI Study, abstr 52. Abstr. Conf Retroviruses Opportun Infect.
38. Pandrea I, Gaufin T, Gautam R, Kristoff J, Mandell D, Montefiori D, Keele BF, Ribeiro RM, Veazey RS, Apetrei C. 2011 Functional cure of SIVagm infection in rhesus macaques results in complete recovery of CD4+ T cells and is reverted by CD8+ cell depletion. PLoS Pathog 7:e1002170. http://dx.doi.org/10.1371/journal.ppat.1002170.
39. Lafeuillade A, Poggi C, Chadapaud S, Hittinger G, Khiri H, Halfon P. 2001. Impact of immune interventions on proviral HIV-1 DNA decay in patients receiving highly active antiretroviral therapy. HIV Med 2:189-194. http://dx.doi.org/10.1046/j.1468-1293.2001.00065.x.
40. Cockerham LR, Deeks SG. 2014. Biomarker reveals HIV's hidden reservoir. eLife 3:e04742. http://dx.doi.org/10.7554/eLife.04742.
41. Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, Yassine-Diab B, Boucher G, Boulassel MR, Ghattas G, Brenchley JM, Schacker TW, Hill BJ, Douek DC, Routy JP, Haddad EK, Sékaly RP. 2009. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 15:893-900. http://dx.doi.org/10.1038/nm.1972.
42. Hatano H. 2013. Immune activation and HIV persistence: considerations for novel therapeutic interventions. Curr Opin HIV AIDS 8:211-216. http://dx.doi.org/10.1097/COH.0b013e32835f9788.
43. Shytaj IL, Savarino A. 2013. A cure for AIDS: a matter of timing?. Retrovirology 10:145. http://dx.doi.org/10.1186/1742-4690-10-145.
44. Deeks SG, Kitchen CM, Liu L, Guo H, Gascon R, Narváez AB, Hunt P, Martin JN, Kahn JO, Levy J, McGrath MS, Hecht FM. 2004. Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood 104:942-947. http://dx.doi.org/10.1182/blood-2003-09-3333.
45. Xu H, Wang X, Lackner AA, Veazey RS. 2013. CD8 down-regulation and functional impairment of SIV-specific cytotoxic T lymphocytes in lymphoid and mucosal tissues during SIV infection. J Leukoc Biol 93:943-950. http://dx.doi.org/10.1189/jlb.1112580.
46. Zhao G, Perilla JR, Yufenyuy EL, Meng X, Chen B, Ning J, Ahn J, Gronenborn AM, Schulten K, Aiken C, Zhang P. 2013. Mature HIV-1 capsid structure by cryo-electron microscopy and all-atom molecular dynamics. Nature 497:643-646. http://dx.doi.org/10.1038/nature12162.
47. Bacchetti P, Deeks SG, McCune JM. 2011. Breaking free of sample size dogma to perform innovative translational research. Sci Transl Med 3:87ps24. http://dx.doi.org/10.1126/scitranslmed.3001628.
48. Hütter G, Nowak D, Mossner M, Ganepola S, Müssig A, Allers K, Schneider T, Hofmann J, Kücherer C, Blau O, Blau IW, Hofmann WK, Thiel E. 2009. Long-term control of HIV by CCR5 Delta32/Delta32 stemcell transplantation. N Engl J Med 360:692-698. http://dx.doi.org/10.1056/NEJMoa0802905.
49. Olsen DB, Davies ME, Handt L, Koeplinger K, Zhang NR, Ludmerer SW, Graham D, Liverton N, MacCoss M, Hazuda D, Carroll SS. 2011. Sustained viral response in a hepatitis C virus-infected chimpanzee via a combination of direct-acting antiviral agents. Antimicrob Agents Chemother 55:937-939. http://dx.doi.org/10.1128/AAC.00990-10.
50. Hron T, Fábryová H, Pa Es J, Elleder D. 2014. Endogenous lentivirus in Malayan colugo (Galeopterus variegatus), a close relative of primates. Retrovirology 11:84. http://dx.doi.org/10.1186/s12977-014-0084-x.
51. Archer J, Weber J, Henry K, Winner D, Gibson R, Lee L, Paxinos E, Arts EJ, Robertson DL, Mimms L, Quiñones-Mateu ME. 2012. Use of four next-generation sequencing platforms to determine HIV-1 coreceptor tropism. PLoS One 7:e49602. http://dx.doi.org/10.1371/journal.pone.0049602.